<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03103152</url>
  </required_header>
  <id_info>
    <org_study_id>isrctn91422391</org_study_id>
    <nct_id>NCT03103152</nct_id>
  </id_info>
  <brief_title>A Study to Examine the Effectiveness of Aspirin and/or Vitamin D3 to Prevent Prostate Cancer Progression</brief_title>
  <acronym>PROVENT</acronym>
  <official_title>PROVENT: A Randomised, Double Blind, Placebo Controlled Feasibility Study to Examine the Clinical Effectiveness of Aspirin and/or Vitamin D3 to Prevent Disease Progression in Men on Active Surveillance for Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen Mary University of London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Barts and the London School of Medicine and Dentistry</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Queen Mary University of London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the acceptability and feasibility of recruitment to a randomised&#xD;
      chemoprevention study of standard (300mg) or low dose (100mg) aspirin vs. placebo and/or&#xD;
      Vitamin D3 vs. placebo in patients enrolled on an Active Surveillance programme for prostate&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The PROVENT study is a randomised, double blind, placebo controlled feasibility study to&#xD;
      examine the clinical effectiveness of aspirin and/or Vitamin D3 to prevent disease&#xD;
      progression in men on Active Surveillance for prostate cancer&#xD;
&#xD;
      The main outcome measure of the trial is the rate of patient recruitment to a randomised&#xD;
      chemoprevention study in men enrolled on an Active Surveillance programme for prostate cancer&#xD;
&#xD;
      Secondary outcomes include the response to treatment as determined by serial multi-parametric&#xD;
      magnetic resonance imaging (MRI) of the prostate, biochemical disease progression and&#xD;
      histological disease progression after 12 months of therapy and finally toxicity and/or&#xD;
      allergy to both aspirin and Vitamin D3.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Actual">March 31, 2020</completion_date>
  <primary_completion_date type="Actual">March 31, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of patient recruitment to a randomised chemoprevention study in men enrolled on an Active Surveillance programme for prostate cancer. Number accrued per month.</measure>
    <time_frame>12 months</time_frame>
    <description>The proportion of eligible patients that join the trial over the 12-month trial recruitment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response to treatment as determined by serial multi-parametric magnetic resonance imaging (MRI) of the prostate. New lesion present or existing lesion + or - in size.</measure>
    <time_frame>3 years</time_frame>
    <description>Lesion on multi-parametric imaging where no MRI lesion at screening. An MRI scan shows a screening + or - in volume by &gt; 33%, or an upgrading of MRI stage of disease to ≥3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical disease progression.</measure>
    <time_frame>12 months</time_frame>
    <description>50% increase in serum Prostate Specific Antigen at 12 months from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological disease progression. Increase in Gleason score or MCCL</measure>
    <time_frame>3 years</time_frame>
    <description>Histological disease progression will be defined as an increase in Gleason scores from: Gleason 3+3 to Gleason score 7 or higher Gleason 3+4 (score 7) to 4+3 (score 7) or Gleason 4+3 to a higher score&#xD;
Or a 50% increase in maximum cancer core length (MCCL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity and/or allergy to both aspirin and Vitamin D3; Symptoms of Aspirin or Vit D toxicity.</measure>
    <time_frame>3 years</time_frame>
    <description>Aspirin toxicity: Haemorrhagic stroke, anaphylaxis following administration, gastrointestinal bleeding requiring intervention (both medical and surgical)&#xD;
Vitamin D3 toxicity: Hypercalcaemia, Anaphylaxis</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>High dose Aspirin &amp; Vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin high dose (300mgs) daily &amp; Vitamin D 4,000 IU (0.1mg) per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose Aspirin, Vitamin D placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high dose aspirin (300mgs) daily and Vitamin D placebo (Miglyol®812 Oil)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose Aspirin , Vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose aspirin (100mgs) daily &amp; Vitamin D 4,000 IU (0.1mg) per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose Aspirin, Vitamin D placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Low dose aspirin (100mgs) daily and Vitamin D placebo (Miglyol®812 Oil)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin Placebo, Vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin placebo and Vitamin D active ingredient - Vigantol® Oil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin placebo, Vitamin D placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin placebo and Vitamin D placebo - Miglyol®812 Oil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose Aspirin &amp; Vitamin D</intervention_name>
    <description>Aspirin 1 x 300mg tablet daily &amp; Vitamin D 4,000IU daily. (8 drops).</description>
    <arm_group_label>High dose Aspirin &amp; Vitamin D</arm_group_label>
    <other_name>Aspirin - acetylsalicylic acid</other_name>
    <other_name>Vitamin D - Vigantol® Oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose Aspirin, Vitamin D placebo</intervention_name>
    <description>Aspirin 1 x 300mg tablet daily &amp; Vitamin D placebo (8 drops).</description>
    <arm_group_label>High dose Aspirin, Vitamin D placebo</arm_group_label>
    <other_name>Aspirin - acetylsalicylic acid</other_name>
    <other_name>Vitamin D placebo - Miglyol®812 Oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose Aspirin , Vitamin D</intervention_name>
    <description>Aspirin 1 x 100mg tablet daily &amp; Vitamin D 4,000IU daily. (8 drops).</description>
    <arm_group_label>Aspirin Placebo, Vitamin D</arm_group_label>
    <arm_group_label>Low dose Aspirin , Vitamin D</arm_group_label>
    <other_name>Aspirin - acetylsalicylic acid</other_name>
    <other_name>Vitamin D - Vigantol® Oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose Aspirin, Vitamin D placebo</intervention_name>
    <description>Aspirin 1 x 100mg tablet daily &amp; Vitamin D placebo 8 drops daily.</description>
    <arm_group_label>Low dose Aspirin, Vitamin D placebo</arm_group_label>
    <other_name>Aspirin - acetylsalicylic acid</other_name>
    <other_name>Vitamin D placebo - Miglyol®812 Oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin Placebo, Vitamin D</intervention_name>
    <description>Aspirin 1 x 300mg placebo tablet daily &amp; Vitamin D 4,000IU daily. (8 drops).</description>
    <arm_group_label>Aspirin Placebo, Vitamin D</arm_group_label>
    <other_name>Vitamin D - Vigantol® Oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin placebo, Vitamin D placebo</intervention_name>
    <description>Aspirin 1 x 100mg placebo tablet daily &amp; Vitamin D 4,000IU daily. (8 drops).</description>
    <arm_group_label>Aspirin placebo, Vitamin D placebo</arm_group_label>
    <arm_group_label>High dose Aspirin, Vitamin D placebo</arm_group_label>
    <other_name>Aspirin Placebo, Vitamin D</other_name>
    <other_name>Vitamin D placebo - Miglyol®812 Oil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. Male subjects aged 16 years or over with an estimated life expectancy of more than&#xD;
             three years&#xD;
&#xD;
          2. Willing and able to provide written informed consent&#xD;
&#xD;
          3. Corrected serum calcium ≤ 2.65mmol/l&#xD;
&#xD;
          4. No previous treatment for prostate cancer (including surgery, hormone therapy,&#xD;
             radiotherapy, cryotherapy)&#xD;
&#xD;
          5. Must have undergone a multi-parametric MRI of the prostate, deemed assessable by the&#xD;
             local radiologist, and any lesions seen must have undergone targeted biopsy,&#xD;
             (transrectal or transperineal) within 12 months of study registration.&#xD;
&#xD;
          6. Histologically confirmed prostate cancer* following prostate biopsy (including at&#xD;
             least 10 cores of prostate tissue) in men opting for Active Surveillance as their&#xD;
             primary cancer therapy.&#xD;
&#xD;
               -  PROVENT Prostate Cancer Criteria. All must be met for Inclusion:&#xD;
&#xD;
                    -  Gleason score 6 or 7 (Gleason 3+3 or 3+4)&#xD;
&#xD;
                    -  Clinical and radiological stage &lt;T3&#xD;
&#xD;
                    -  Serum Prostate Specific Antigen (PSA) ≤15.0 ng/ml&#xD;
&#xD;
                    -  Less than 10mm of cancer in a single core&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previously treated prostate cancer (including radiotherapy, hormone therapy,&#xD;
             brachytherapy or surgery)&#xD;
&#xD;
          2. Currently enrolled, or has been a participant within the last 30 days, in any other&#xD;
             investigational drug or device study.&#xD;
&#xD;
          3. Current daily use of aspirin or NSAIDs; or daily dietary supplements/medication&#xD;
             containing more than 400 IU (10 micrograms per day) Vitamin D; or chronic use (defined&#xD;
             as &gt; 6 months continuous daily use) of either aspirin or &gt;400IU Vitamin D within two&#xD;
             years of study enrolment&#xD;
&#xD;
          4. Current or previous use of 5-α reductase inhibitors such as finasteride or dutasteride&#xD;
&#xD;
          5. Not willing to comply with the procedural requirements of this protocol including&#xD;
             repeat prostate biopsies&#xD;
&#xD;
          6. Known allergy/sensitivity to or intolerance of aspirin, other salicylates or NSAIDs&#xD;
             e.g. ibuprofen/ naproxen&#xD;
&#xD;
          7. Prior history of gastro-intestinal bleeding or ulceration, severe dyspepsia or&#xD;
             inflammatory bowel disease&#xD;
&#xD;
          8. Haemophilia or other bleeding diatheses&#xD;
&#xD;
          9. Prior history of renal stone disease&#xD;
&#xD;
         10. Chronic renal disease (≥stage 4)&#xD;
&#xD;
         11. Known hypercalcaemia (corrected serum calcium &gt;2.65 mmol/l) or untreated&#xD;
             hyperparathyroidism&#xD;
&#xD;
         12. Any bowel condition that would make repeat transrectal biopsy hazardous or difficult&#xD;
             to perform e.g. recto-urethral fistula, or prior bowel surgery such as&#xD;
             abdomino-perineal resection.&#xD;
&#xD;
         13. Any malignancy (other than non-melanoma skin cancer) that has not been in complete&#xD;
             remission for five years&#xD;
&#xD;
         14. Any serious co-existent medical condition that would make repeat prostate biopsy&#xD;
             hazardous e.g. anti-coagulation requiring continuous administration&#xD;
&#xD;
         15. Severe Asthma&#xD;
&#xD;
         16. G6PD ( glucose-6-phosphate dehydrogenase) deficiency&#xD;
&#xD;
         17. Pre-existing macular degeneration&#xD;
&#xD;
         18. All contraindications to aspirin and Vitamin D3 (e.g. Sarcoidosis), including&#xD;
             concomitant therapy with any medication that may interact with aspirin or Vitamin D3&#xD;
             (see section 4.10)&#xD;
&#xD;
         19. Tuberculosis&#xD;
&#xD;
         20. Regular consumption of alcohol units greater than the recommended daily limit of 3-4&#xD;
             units per day (men)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Greg Shaw, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen Mary London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jack Cuzick, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Queen Mary London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Darent Valley Hospital</name>
      <address>
        <city>Dartford</city>
        <zip>DA2 8DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>London</city>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital UHCW NHS Trust</name>
      <address>
        <city>London</city>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Bartholomews Hospital London, Bart's and the London school of Medicine</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College Hospital London</name>
      <address>
        <city>London</city>
        <zip>NW1 2B</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Homerton Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <zip>S016 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 21, 2016</study_first_submitted>
  <study_first_submitted_qc>April 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2017</study_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>Active Surveillance</keyword>
  <keyword>Chemo-prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>March 10, 2021</submitted>
    <returned>April 8, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

